Focused lung panel informs the use of targeted cancer therapies: Ying-Chun Lo, M.D., Ph.D.
Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making. The focused panel includes key DNA and RNA components and can provide rapid results from a range of patient specimens.
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:32)
Could you provide us some background about yourself?
(01:34)
Could you give us a brief overview of the new Mayo complete lung cancer assay?
(03:31)
Can you talk a little bit more about the specific genes and why they're important for patient care?
(04:53)
When would a clinician pathologist order a focused NGS panel, such as this new Mayo complete lung cancer panel, over a larger cancer panel?
(07:27)
What specimens are accepted for the Mayo complete lung cancer panel?
(08:50)
How are these molecular results used in patient care?